References
- WHO Expert Consultation on Rabies prevention. Third report. Technical report series no. 1012. Geneva: World Health Organization; 2018.
- World Health Organization. Rabies vaccines: WHO position paper. Weekly Epidemiological Record, No. 16. 2018;93:201–20.
- World Health Organization. Human and dog rabies prevention and control. Report of the WHO/Bill & Melinda Gates Foundation consultation. Annecy (France); 2009. p. 9.
- Knobel DL, Cleaveland S, Coleman PG, Fèvre EM, Meltzer MI, Miranda ME, Shaw A, Zinsstag J, Meslin F-X. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005;83(5):360–68.
- World Health Organization. Rabies vaccines and immunoglobulins: WHO position,WHO/CDS/NTD/NZD/2018.04. Geneva (Switzerland): World Health Organization; 2018.
- World Health Organization. WHO Expert Consultation on Rabies. Second report. Technical report series no. 931. Geneva (Switzerland): World Health Organization; 2005.
- World Health Organization. WHO Expert Committee on Rabies. 8th report. Technical report series no.824. Geneva (Switzerland): World Health Organization; 1992. p. 10–16.
- Ravish HS, Rachana AR, Veena V, Ashwath Narayana DH. Compliance to anti-rabies vaccination in post-exposure prophylaxis. Indian J Public Health. 2015;59(1):58–60. doi:10.4103/0019-557X.152867.
- World Health Organization. WHO Expert Consultation on Rabies. Second report. Technical report series no. 982. Geneva (Switzerland): World Health Organization; 2013.
- The Morbidity and Mortality Weekly Report, Center for Disease Control and Prevention (CDC). Use of a reduced (4-dose) vaccine schedule for post-exposure prophylaxis to prevent human rabies. Recommend Advisory Committee Immun Prac. 2010;59(RR02):1–10.
- Sudarshan MK, Mahendra BJ, Madhusudana SN, Ashwoath Narayana DH, Rahman A, Rao NS, Meslin X, Lobo F, Ravikumar D, Gangaboraiah K. An epidemiological study of animal bites in India: results of a WHO sponsored national multi-centric rabies survey. J Commun Dis. 2006;38(1):32–39. PMID:17370688
- Zalan E, Wilson C, Pukitis D. A microtest for the quantitation of rabies virus neutralizing antibodies. J Biol Stand. 1979;7(3):213–20. doi:10.1016/S0092-1157(79)80024-4.
- World Health Organization. Rabies post exposure prophylaxis. [accessed 2017 Jul 20]. http://www.who.int/rabies/human/postexp.
- Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. Global alliance for rabies control partners for rabies prevention. Estimating the global burden of endemic canine rabies. PLoSNegl Trop Dis. 2015 Apr 16;9(4):3709.
- World Health Organization. Rabies. [accessed 2017 Jul 18]. http://www.who.int/mediacentre/factsheets.
- Wilde H, Khawplod P, Khamoltham T, Hemachudha T, Tepsumethanon V, Lumlerdacha B, Mitmoonpitak C, Sitprija V. Rabies control in South and Southeast Asia. Vaccine. 2005 Mar 18;23(17–18):2284–89. doi:10.1016/j.vaccine.2005.01.030.
- WHO South East Asia region: strategic framework for elimination of human rabies transmitted by dogs in the South-East Asia Region: world Health Organization, Regional office for South East Asia; 2012.
- Jackson AC, William HW. Rabies. 2nd ed. London (United Kingdom): Elsevier academic press; 2007. p. 32–56.
- Barth R, Bijok U, Gruschkau H, Smerdel S, Vodopija I. Purified chick embryo cell rabies vaccine for human use. Lancet. 1984;1:7.
- World Health Organization (WHO). Rabies vaccines, WHO position paper. Weekly Epidemiological Record. 2002 Apr 5;14(77):109–20.
- Zang ZF. Rabies and rabies research: past, present and future. Vaccine. 1997;15:20–24. doi:10.1016/S0264-410X(96)00312-X.
- Vodopija I, Sureau P, Lafon M, Baklaic Z, Ljubicic M, Svjetlicic M, Smerdel S. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule. Vaccine. 1986;4:245–48. doi:10.1016/0264-410X(86)90138-6.
- Chutivongse S, Wilde H, Fishbein DB, Baer GM, Hemachudha T. One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine. 1991;9(8):573–76. doi:10.1016/0264-410X(91)90244-Z.
- Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine. 2009;28(1):1–8.
- Sudarshan MK, Bhardwaj S, Mahendra BJ, Sharma H, Sanjay TV, Ashwathnarayana DH. An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax®) in Indian subjects. Hum Vaccin. 2008;4(4):275–79. doi:10.4161/hv.4.4.5588.
- Mahendra BJ, Madhusudana SN, Ashwathnarayana DH, Sampath G, Datta SS, Sudarshan MK, Venkatesh GM, Muhamuda K, Bilagumba G, Shamanna M et al. A comparative study on the immunogenicity, safety and tolerance of purified duck embryo vaccine (PDEV) manufactured in India (Vaxirab) and Switzerland (Lyssavac-N): A randomized simulated post-exposure study in healthy volunteers. Vaccine. 2007 Dec 5;25(50):8405–09. doi:10.1016/j.vaccine.2007.10.002.
- Ashwath Narayana DH, Madhusudana SN, Sampath G, Sathpathy DM, Mankeshwar R, Haradanhalli S, Ravish, et al. A comparative study on the safety and immunogenicity of purified duck embryo cell vaccine (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purified vero cell rabies vaccine (PVRV, Verorab). Vaccine. 2010;28:148–51. doi:10.1016/j.vaccine.2009.09.090.
- Sustainable development goals: 17 goals to transform our world. Goal 3: ensure healthy lives and promote well-being for all at all ages. [accessed 2018 Feb 16]. http://www.un.org/sustainabledevelopment/health.